Tocqueville Asset Management L.P. Alnylam Pharmaceuticals, Inc. Transaction History

Tocqueville Asset Management L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $368,910 - $441,000	-3,000 Closed	0 $0
Q4 2019 Jan 14, 2020	BUY	$74.51 - $124.23 $223,530 - $372,690	3,000 New	3,000 $346,000
Q2 2019 Jul 31, 2019	SELL	$65.86 - $92.79 $507,122 - $714,483	-7,700 Closed	0 $0
Q1 2019 Apr 30, 2019	BUY	$72.76 - $93.45 $560,252 - $719,565	7,700 New	7,700 $720,000
Q4 2018 Feb 08, 2019	SELL	$62.67 - $88.33 $2.66 Million - $3.75 Million	-42,481 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$87.52 - $122.67 $1.07 Million - $1.5 Million	-12,235 Reduced 22.36%	42,481 $3.72 Million
Q2 2018 Aug 13, 2018	SELL	$88.31 - $107.8 $1.92 Million - $2.34 Million	-21,745 Reduced 28.44%	54,716 $5.39 Million
Q1 2018 May 14, 2018	SELL	$115.92 - $148.54 $8.99 Million - $11.5 Million	-77,575 Reduced 50.36%	76,461 $9.11 Million
Q4 2017 Feb 13, 2018	BUY	$114.49 - $139.98 $15.3 Million - $18.7 Million	133,261 Added 641.45%	154,036 $19.6 Million
Q3 2017 Oct 30, 2017	BUY	$72.53 - $118.27 $1.51 Million - $2.46 Million	20,775	20,775 $2.44 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.